298 related articles for article (PubMed ID: 22154891)
1. Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.
Getlik M; Grütter C; Simard JR; Nguyen HD; Robubi A; Aust B; van Otterlo WA; Rauh D
Eur J Med Chem; 2012 Feb; 48():1-15. PubMed ID: 22154891
[TBL] [Abstract][Full Text] [Related]
2. 5-amino-pyrazoles as potent and selective p38α inhibitors.
Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336
[TBL] [Abstract][Full Text] [Related]
3. Enhanced selectivity profile of pyrazole-urea based DFG-out p38alpha inhibitors.
Liu H; Kuhn C; Feru F; Jacques SL; Deshmukh GD; Ye P; Rennie GR; Johnson T; Kazmirski S; Low S; Coli R; Ding YH; Cheng AC; Tecle H; English JM; Stanton R; Wu JC
Bioorg Med Chem Lett; 2010 Aug; 20(16):4885-91. PubMed ID: 20620059
[TBL] [Abstract][Full Text] [Related]
4. Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors.
Lin S; Wrobleski ST; Hynes J; Pitt S; Zhang R; Fan Y; Doweyko AM; Kish KF; Sack JS; Malley MF; Kiefer SE; Newitt JA; McKinnon M; Trzaskos J; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2010 Oct; 20(19):5864-8. PubMed ID: 20732813
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Jin CH; Sreenu D; Krishnaiah M; Subrahmanyam VB; Rao KS; Nagendra Mohan AV; Park CY; Son JY; Son DH; Park HJ; Sheen YY; Kim DK
Eur J Med Chem; 2011 Sep; 46(9):3917-25. PubMed ID: 21696866
[TBL] [Abstract][Full Text] [Related]
6. The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor.
Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Schieven GL; Gillooly KM; Shuster DJ; Taylor TL; Yang X; McIntyre KW; McKinnon M; Zhang H; Marathe PH; Doweyko AM; Kish K; Kiefer SE; Sack JS; Newitt JA; Barrish JC; Dodd J; Leftheris K
Bioorg Med Chem Lett; 2008 Mar; 18(6):1762-7. PubMed ID: 18313298
[TBL] [Abstract][Full Text] [Related]
7. Identification of triazolopyridazinones as potent p38α inhibitors.
Herberich B; Jackson C; Wurz RP; Pettus LH; Sherman L; Liu Q; Henkle B; Saris CJ; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2012 Jan; 22(2):1226-9. PubMed ID: 22196117
[TBL] [Abstract][Full Text] [Related]
8. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
Goettert M; Schattel V; Koch P; Merfort I; Laufer S
Chembiochem; 2010 Dec; 11(18):2579-88. PubMed ID: 21108268
[TBL] [Abstract][Full Text] [Related]
9. Displacement assay for the detection of stabilizers of inactive kinase conformations.
Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
[TBL] [Abstract][Full Text] [Related]
10. Benzothiazole based inhibitors of p38alpha MAP kinase.
Liu C; Lin J; Pitt S; Zhang RF; Sack JS; Kiefer SE; Kish K; Doweyko AM; Zhang H; Marathe PH; Trzaskos J; Mckinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Mar; 18(6):1874-9. PubMed ID: 18296051
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL
Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
Swahn BM; Huerta F; Kallin E; Malmström J; Weigelt T; Viklund J; Womack P; Xue Y; Ohberg L
Bioorg Med Chem Lett; 2005 Nov; 15(22):5095-9. PubMed ID: 16140012
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors.
McIntyre NA; McInnes C; Griffiths G; Barnett AL; Kontopidis G; Slawin AM; Jackson W; Thomas M; Zheleva DI; Wang S; Blake DG; Westwood NJ; Fischer PM
J Med Chem; 2010 Mar; 53(5):2136-45. PubMed ID: 20146435
[TBL] [Abstract][Full Text] [Related]
14. Targeting the hinge glycine flip and the activation loop: novel approach to potent p38α inhibitors.
Martz KE; Dorn A; Baur B; Schattel V; Goettert MI; Mayer-Wrangowski SC; Rauh D; Laufer SA
J Med Chem; 2012 Sep; 55(17):7862-74. PubMed ID: 22897496
[TBL] [Abstract][Full Text] [Related]
15. Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors.
Dai Y; Hartandi K; Soni NB; Pease LJ; Reuter DR; Olson AM; Osterling DJ; Doktor SZ; Albert DH; Bouska JJ; Glaser KB; Marcotte PA; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2008 Jan; 18(1):386-90. PubMed ID: 18023347
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of novel 4,5-diphenylthiazole derivatives as potential acyl-CoA:cholesterol O-acyltransferase inhibitors.
Romeo G; Salerno L; Milla P; Siracusa M; Cattel L; Russo F
Pharmazie; 1999 Jan; 54(1):19-23. PubMed ID: 9987793
[TBL] [Abstract][Full Text] [Related]
17. Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz RP; Pettus LH; Xu S; Henkle B; Sherman L; Plant M; Miner K; McBride H; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2009 Aug; 19(16):4724-8. PubMed ID: 19574047
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796).
Regan J; Capolino A; Cirillo PF; Gilmore T; Graham AG; Hickey E; Kroe RR; Madwed J; Moriak M; Nelson R; Pargellis CA; Swinamer A; Torcellini C; Tsang M; Moss N
J Med Chem; 2003 Oct; 46(22):4676-86. PubMed ID: 14561087
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 5-substituted-N-arylpyridazinones as inhibitors of p38 MAP kinase.
Jerome KD; Hepperle ME; Walker JK; Xing L; Devraj RV; Benson AG; Baldus JE; Selness SR
Bioorg Med Chem Lett; 2010 May; 20(10):3146-9. PubMed ID: 20395140
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors.
Bhattacharya SK; Aspnes GE; Bagley SW; Boehm M; Brosius AD; Buckbinder L; Chang JS; Dibrino J; Eng H; Frederick KS; Griffith DA; Griffor MC; Guimarães CR; Guzman-Perez A; Han S; Kalgutkar AS; Klug-McLeod J; Garcia-Irizarry C; Li J; Lippa B; Price DA; Southers JA; Walker DP; Wei L; Xiao J; Zawistoski MP; Zhao X
Bioorg Med Chem Lett; 2012 Dec; 22(24):7523-9. PubMed ID: 23153798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
